Kazia Therapeutics Limited (NASDAQ:KZIA – Free Report) shares are going to reverse split before the market opens on Monday, October 28th. The 1-10 reverse split was announced on Tuesday, October 15th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, October 25th.
Kazia Therapeutics Trading Down 1.5 %
Shares of NASDAQ KZIA opened at $0.52 on Friday. The business’s 50 day moving average price is $0.40 and its 200-day moving average price is $0.36. Kazia Therapeutics has a fifty-two week low of $0.19 and a fifty-two week high of $1.58.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a “buy” rating and set a $2.00 target price on shares of Kazia Therapeutics in a research report on Friday, July 12th.
About Kazia Therapeutics
Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma.
Featured Articles
- Five stocks we like better than Kazia Therapeutics
- What is Short Interest? How to Use It
- Texas Roadhouse Stock Steering for New Highs This Year
- What is an Earnings Surprise?
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Trading Halts Explained
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Kazia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kazia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
